BridgeMD
New treatment option for Solid Tumor
Official title Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer
ClinicalTrials.gov ID: NCT06667960
What this study is testing
What is JK06?
JK06 is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for solid tumor.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of intravenously administered JK06 in patients with unresectable locally, advanced or metastatic cancer.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years old.
- Signed informed consent and willing and able to comply with study procedures and scheduled visits.
- For Dose Escalation, patients with histologically diagnosed unresectable, locally advanced, or metastatic solid tumors.
- Dose expansion solid tumor groups.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.
You likely can't join if
- Patients with symptomatic or unstable CNS primary tumor or metastases and/or carcinomatous meningitis. Patients with documented treated CNS...
- Major surgery within 6 weeks from treatment initiation.
- Clinically significant cardiovascular/vascular disease ≤ 6 months before first dose.
- Clinically significant gastrointestinal disorders.
- Clinically significant pulmonary compromise requiring supplemental oxygen use.
- Grade 2 or greater peripheral neuropathy at time of study entry.
See the full eligibility criteria
- Age ≥ 18 years old.
- Signed informed consent and willing and able to comply with study procedures and scheduled visits.
- For Dose Escalation, patients with histologically diagnosed unresectable, locally advanced, or metastatic solid tumors.
- Dose expansion solid tumor groups.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.
- Life expectancy ≥ 12 weeks.
- Measurable disease as per RECIST 1.1 criteria and documented by CT and/or MRI. Note: lesions treated previously with radiation must demonstrate clear evidence of radiographic progression since the completion of prior...
- Acceptable laboratory parameters:
- Albumin ≥ 2.8 g/dL.
- Platelet count ≥ 100, 000.
- Hemoglobin ≥ 9.0 g/dL.
- Absolute neutrophil count ≥ 1,500/μL.
- ALT/AST ≤ 3.0 times ULN. \- ALT/AST ≤ 5 × ULN for patients with liver metastases.
- Total bilirubin ≤ 1.5 ULN or ≤ 3 x ULN for patients with Gilbert's disease.
- Direct bilirubin ≤ 1.5 ULN for patients with total bilirubin \> 1.5 ULN.
- Creatinine ≤ 1.8 mg/dL. -Or calculated/measured creatinine clearance \> 30 mL/minute.
- Identification of an archival tumor sample (i.e., tissue block (formalin-fixed paraffin-embedded [FFPE]) or a series of approximately 10-15 slides).
- Consent to pre-treatment fresh tumor biopsy for patients enrolled in the back-fill part of Dose Escalation and all eligible patients enrolled in Cohort Expansion.
- Women of childbearing potential (WOCBP) not surgically sterilized and between menarche and 1 year post menopause must have a negative serum or urine pregnancy test and be willing to use 2 forms of effective...
- Male patients with partners of childbearing potential, even if surgically sterilized (i.e., status post-vasectomy) must agree to contraceptive use from the time of consent through 217 days after treatment...
- Central nervous system (CNS) metastases must have been treated, be asymptomatic for ≥ 14 days, and meet certain criteria at the time of enrollment.
- Must be willing and able to comply with clinic visits and procedures outlined in the study protocol.
- Concurrent use of hormones for breast cancer or for non-cancer related conditions (e.g., insulin for diabetes, hormone replacement therapy) is acceptable. Bisphosphonates or RANK-L inhibitors or analogues are permitted...
- Patients with symptomatic or unstable CNS primary tumor or metastases and/or carcinomatous meningitis. Patients with documented treated CNS metastases stable for at least 4 weeks may be enrolled at the discretion of the...
- Major surgery within 6 weeks from treatment initiation.
- Clinically significant cardiovascular/vascular disease ≤ 6 months before first dose.
- Clinically significant gastrointestinal disorders.
- Clinically significant pulmonary compromise requiring supplemental oxygen use.
- Grade 2 or greater peripheral neuropathy at time of study entry.
- Vaccination with any live virus vaccine within 4 weeks prior to the initiation of study drug administration. Inactivated annual influenza vaccination is allowed.
- Known hypersensitivity to JK06 or any excipient.
- Second primary invasive malignancy not in remission for ≥ 1 year. Exceptions include non-melanoma skin cancer, cervical carcinoma in situ, resected melanoma in situ, or any malignancy considered to be indolent and never...
- Any serious underlying medical or psychiatric condition that would preclude understanding and rendering of informed consent or impair the ability of the patient to receive or tolerate the planned treatment.
- Recent or ongoing serious infection.
- Prior systemic anti-cancer treatment:
- For cytotoxic chemotherapy, small molecule inhibitors, radiation, or similar investigational treatments, ≤ 2 weeks or 5 half-lives, whichever is shorter.
- For monoclonal antibodies or similar experimental therapies: ≤ 3 weeks or 5 half-lives, whichever is shorter.
- Antibody drug conjugates and radioimmunoconjugates or other similar experimental therapies ≤ 6 weeks or 5 half-lives, whichever is shorter.
- Ascites or pleural effusions requiring large volume para- or pleurocentesis within 4 weeks of treatment initiation.
- Pregnant or nursing.
- Therapeutic anticoagulation for a thromboembolic event that occurred within 3 months of dosing; prophylactic anticoagulation is permitted.
- Active pneumonitis/interstitial lung disease (ILD) or history of drug-induced or radiation-induced pneumonitis/ILD that requires ongoing systemic corticosteroid treatment or has not fully resolved at study entry.
The study team makes the final eligibility decision.
Where it's taking place
- Antwerp, Belgium
- Brussels, Belgium
- Ghent, Belgium
- Yvoir, Belgium
- Barcelona, Spain
- Madrid, Spain
- Pamplona, Spain
- Rioja, Spain
- Valencia, Spain
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Antwerp, Belgium; Brussels, Belgium; Ghent, Belgium; Yvoir, Belgium; Barcelona, Spain; Madrid, Spain and 3 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.